Teva

Latest stories

8h
Market Watch
Is the new Teva x Ugg collection fashion-forward or just plain ugly?Models wear shoes from the new Teva x Ugg collection Here are some of the ques
Is the new Teva x Ugg collection fashion-forward or just plain ugly?
Market Watch / Posted 8 hours ago
Models wear shoes from the new Teva x Ugg collection Here are some of the questions you might ask yourself after seeing the new shoes created through a Teva and Ugg mashup: “Why is this a thing?” “Who would wear these?” “Are these the ugliest... Read more
1d
Morningstar
Looking Abroad for Quality Bargainsgeneric market growth and recent generic competition on oral multiple sclerosis
Looking Abroad for Quality Bargains
Morningstar / Posted yesterday
generic market growth and recent generic competition on oral multiple sclerosis drug Copaxone create big hurdles for Teva. However, he notes, Teva still has many competitive advantages that should help uphold earnings. The company's large... Read more
2d
CNBC
Mylan CEO's testimony was a huge blow to the entire pharma industrywhen the company executed a tax inversion to The Netherlands in 2015 after it t
Mylan CEO's testimony was a huge blow to the entire pharma industry
CNBC / Posted 2 days ago
when the company executed a tax inversion to The Netherlands in 2015 after it turned down a purchase offer from rival Teva valued at more than twice today's stock price. Under its procedures shareholders don't get to nominate board members;... Read more
3d
Philly.com
Suit: Drugmaker Cephalon responsible for patient's death in opioid overdoseit was not approved to treat led to his addiction. The suit against the Cheste
Suit: Drugmaker Cephalon responsible for patient's death in opioid overdose
Philly.com / Posted 3 days ago
it was not approved to treat led to his addiction. The suit against the Chester County-based company and its parent, Teva Pharmaceuticals, is intended to target manufacturers for their role in an epidemic that has resulted in more than... Read more
3d
Guelph Mercury
The billion-dollar race for the ugliest shoessell people on awkward, curvy cork wedges. It's as if everyone's racing to make
The billion-dollar race for the ugliest shoes
Guelph Mercury / Posted 3 days ago
sell people on awkward, curvy cork wedges. It's as if everyone's racing to make the ugliest shoe. And on Friday, Ugg and Teva took the plunge into the widening sea of unpretty footwear. There is, apparently, a strategy afoot. The brands, both... Read more
3d
FOX News
Mesoblast Cell Treatment Shows Promise In Rheumatoid Arthritis, Study FindsIt causes inflammation and potentially destruction of multiple joints. Mesobla
Mesoblast Cell Treatment Shows Promise In Rheumatoid Arthritis, Study Finds
FOX News / Posted 3 days ago
It causes inflammation and potentially destruction of multiple joints. Mesoblast, which is 14.6-percent owned by Teva Pharmaceutical Industries, said it plans to line up a partner to help it move the treatment into larger Phase III... Read more
3d
The Jewish Press
New Israeli Crowdfunding Platform Starts Micro Funds Named After Donors [video]Prof. Meir Heth, Israel’s former Banks Commissioner, Tel-Aviv Stock Exchange Ch
New Israeli Crowdfunding Platform Starts Micro Funds Named After Donors [video]
The Jewish Press / Posted 3 days ago
Prof. Meir Heth, Israel’s former Banks Commissioner, Tel-Aviv Stock Exchange Chairman , Bank Leumi Chairman and Chairman of Teva Pharmaceuticals. The credit rating for ventures, will be performed by the international rating agency D&B. Social... Read more
3d
Business Wire
ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Canceragreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordat
ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer
Business Wire / Posted 3 days ago
agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. ERYTECH is listed on Euronext regulated market in Paris... Read more
3d
Business Wire
ERYTECH schließt Aufnahme von Patienten in Phase-Studie zu Eryaspase (GRASPA®) bei Pankreaskrebs abOrphan Europe (Recordati-Gruppe) eine Lizenz- und Vertriebspartnerschaft für Er
ERYTECH schließt Aufnahme von Patienten in Phase-Studie zu Eryaspase (GRASPA®) bei Pankreaskrebs ab
Business Wire / Posted 3 days ago
Orphan Europe (Recordati-Gruppe) eine Lizenz- und Vertriebspartnerschaft für Eryaspase bei ALL und AML in Europa und mit TEVA für ALL in Israel getroffen, die das Medikament unter dem Markennamen GRASPA® vermarkten werden. ERYTECH ist am... Read more
708 related stories
4d
Boston Globe
Drug makers push ahead with novel injectable therapies for migrainesCGRP levels rocket up when headaches attack and normalize when they go away. A
Drug makers push ahead with novel injectable therapies for migraines
Boston Globe / Posted 4 days ago
CGRP levels rocket up when headaches attack and normalize when they go away. And thus four drug makers — Amgen, Eli Lilly, Teva Pharmaceuticals, and Alder Biopharmaceuticals — have fashioned antibodies that can bind to CGRP molecules and block... Read more
5d
FOX Business
3 Dirt-Cheap Dividend Stocks You Can Buy Right Nowbut there are a select few flying under the radar at the moment. AbbVie(NYSE: A
3 Dirt-Cheap Dividend Stocks You Can Buy Right Now
FOX Business / Posted 5 days ago
but there are a select few flying under the radar at the moment. AbbVie(NYSE: ABBV), Gilead Sciences(NASDAQ: GILD), and Teva Pharmaceutical Industries(NYSE: TEVA), for instance, are all trading at steep discounts relative to their peers. Here's... Read more
5d
FOX Business
3 Dirt-Cheap Dividend Stocks You Can Buy Right Nowbut there are a select few flying under the radar at the moment. AbbVie(NYSE: A
3 Dirt-Cheap Dividend Stocks You Can Buy Right Now
FOX Business / Posted 5 days ago
but there are a select few flying under the radar at the moment. AbbVie(NYSE: ABBV), Gilead Sciences(NASDAQ: GILD), and Teva Pharmaceutical Industries(NYSE: TEVA), for instance, are all trading at steep discounts relative to their peers. Here's... Read more
6d
The Hollywood Reporter
Milan Day 3: Versace Glam Slam; Etro's Boho Beat; La Perla Launches Kim Kardashian-Ready RTWto it, from the bedazzled blue evening pajama set that was the finale at the Gi
Milan Day 3: Versace Glam Slam; Etro's Boho Beat; La Perla Launches Kim Kardashian-Ready RTW
The Hollywood Reporter / Posted 6 days ago
to it, from the bedazzled blue evening pajama set that was the finale at the Giorgio Armani show Friday morning, to the Teva-like sport sandals on the runway at Versace Friday night. That's right, Tevas at Versace! Versace’s Glam Slam Playing... Read more
6d
The Economic Times
Sun Pharmaceuticals among bidders for Bayer’s dermatology brandsBloomberg report said. Sun Pharma declined to comment on the development. Apar
Sun Pharmaceuticals among bidders for Bayer’s dermatology brands
The Economic Times / Posted 6 days ago
Bloomberg report said. Sun Pharma declined to comment on the development. Apart from Sun, number one ranked generics giant Teva, Perrigo, Allergan and Spanish pharmaceutical company Almirall in combination with Galderma are also said to be... Read more
7d
Reuters
Vanda Pharmaceuticals prepares to explore a salein the central nervous system sector, has been seeking to deploy around $20 bil
Vanda Pharmaceuticals prepares to explore a sale
Reuters / Posted 7 days ago
in the central nervous system sector, has been seeking to deploy around $20 billion in cash gleaned from a recent deal with Teva Pharmaceuticals (TEVA.TA). (Reporting by Carl O'Donnell in New York; Editing by Alan Crosby and Chizu Nomiyama)Next In... Read more
7d
CNBC
Negative impact largely priced into shares of EpiPen-maker Mylan, analyst saysalso said a generic version of the EpiPen would lead to "essentially the entire
Negative impact largely priced into shares of EpiPen-maker Mylan, analyst says
CNBC / Posted 7 days ago
also said a generic version of the EpiPen would lead to "essentially the entire market" converting. Wilbur said that if Teva Pharmaceuticals does get its own generic version approved, it "could probably capture 25 to 30 percent of the EpiPen... Read more
7d
The Clarion-Ledger
Mylan CEO defends price boosts for lifesaving EpiPenhurdles to innovation that may be blocking competitors. The agency recently del
Mylan CEO defends price boosts for lifesaving EpiPen
The Clarion-Ledger / Posted 7 days ago
hurdles to innovation that may be blocking competitors. The agency recently delayed a prospective competitor offered by Teva Pharmaceutical Industries, leaving Mylan as the only readily available option for most consumers. Rep. Stephen Lynch,... Read more
287 related stories
7d
York Daily Record
Mylan CEO defends price boosts for lifesaving EpiPenhurdles to innovation that may be blocking competitors. The agency recently del
Mylan CEO defends price boosts for lifesaving EpiPen
York Daily Record / Posted 7 days ago
hurdles to innovation that may be blocking competitors. The agency recently delayed a prospective competitor offered by Teva Pharmaceutical Industries, leaving Mylan as the only readily available option for most consumers. Rep. Stephen Lynch,... Read more
287 related stories
7d
Daily Journal
Mylan CEO defends price boosts for lifesaving EpiPenhurdles to innovation that may be blocking competitors. The agency recently del
Mylan CEO defends price boosts for lifesaving EpiPen
Daily Journal / Posted 7 days ago
hurdles to innovation that may be blocking competitors. The agency recently delayed a prospective competitor offered by Teva Pharmaceutical Industries, leaving Mylan as the only readily available option for most consumers. Rep. Stephen Lynch,... Read more
287 related stories
7d
Daily Record
Mylan CEO defends price boosts for lifesaving EpiPenhurdles to innovation that may be blocking competitors. The agency recently del
Mylan CEO defends price boosts for lifesaving EpiPen
Daily Record / Posted 7 days ago
hurdles to innovation that may be blocking competitors. The agency recently delayed a prospective competitor offered by Teva Pharmaceutical Industries, leaving Mylan as the only readily available option for most consumers. Rep. Stephen Lynch,... Read more
287 related stories
7d
Elmira Star-Gazette
Mylan CEO defends price boosts for lifesaving EpiPenhurdles to innovation that may be blocking competitors. The agency recently del
Mylan CEO defends price boosts for lifesaving EpiPen
Elmira Star-Gazette / Posted 7 days ago
hurdles to innovation that may be blocking competitors. The agency recently delayed a prospective competitor offered by Teva Pharmaceutical Industries, leaving Mylan as the only readily available option for most consumers. Rep. Stephen Lynch,... Read more
287 related stories
7d
The Arizona Republic
Mylan CEO defends price boosts for lifesaving EpiPenhurdles to innovation that may be blocking competitors. The agency recently del
Mylan CEO defends price boosts for lifesaving EpiPen
The Arizona Republic / Posted 7 days ago
hurdles to innovation that may be blocking competitors. The agency recently delayed a prospective competitor offered by Teva Pharmaceutical Industries, leaving Mylan as the only readily available option for most consumers. Rep. Stephen Lynch,... Read more
287 related stories
8d
The Register NorthJersey.com
Mylan CEO defends price boosts for lifesaving EpiPenhurdles to innovation that may be blocking competitors. The agency recently del
Mylan CEO defends price boosts for lifesaving EpiPen
The Register NorthJersey.com / Posted 8 days ago
hurdles to innovation that may be blocking competitors. The agency recently delayed a prospective competitor offered by Teva Pharmaceutical Industries, leaving Mylan as the only readily available option for most consumers. Rep. Stephen Lynch,... Read more
287 related stories
8d
11 News Houston
Mylan CEO defends price boosts for lifesaving EpiPenhurdles to innovation that may be blocking competitors. The agency recently del
Mylan CEO defends price boosts for lifesaving EpiPen
11 News Houston / Posted 8 days ago
hurdles to innovation that may be blocking competitors. The agency recently delayed a prospective competitor offered by Teva Pharmaceutical Industries, leaving Mylan as the only readily available option for most consumers. Rep. Stephen Lynch,... Read more
287 related stories
8d
CNBC
Allergan CEO says 'the American people deserve to be angry' at price gougingSaunders added that the performance of Allergan's stock stems from a change in
Allergan CEO says 'the American people deserve to be angry' at price gouging
CNBC / Posted 8 days ago
Saunders added that the performance of Allergan's stock stems from a change in shareholder base as a result of the Teva Pharmaceuticals deal and failed deal with Pfizer this year, bad publicity for the companies engaged in price gouging and the... Read more
8d
The Hill
Pricing structure, not profits, are the problem in the EpiPen scandalthe sordid tale that put Bresch in the hot seat in the first place: ADVERTISEM
Pricing structure, not profits, are the problem in the EpiPen scandal
The Hill / Posted 8 days ago
the sordid tale that put Bresch in the hot seat in the first place: ADVERTISEMENT In 2009, Mylan filed suit against Teva who had came out with a generic EpiPen. The case was settled in 2012, where Teva agreed to not go to market until 2015.... Read more
287 related stories
8d
WVVA Bluefield
Cummings says Mylan hasn't provided EpiPen datafor Mylan's EpiPen. The agency has a backlog of generic drugs under review, in
Cummings says Mylan hasn't provided EpiPen data
WVVA Bluefield / Posted 8 days ago
for Mylan's EpiPen. The agency has a backlog of generic drugs under review, including a version of EpiPen from competitor Teva Pharmaceuticals. But the company said earlier this year that regulators had found problems with its application. Teva's... Read more
287 related stories
8d
Dallas Morning News
House panel slams drug company CEO for EpiPen price hikesa backlog of generic drugs under review. Regulators said earlier this year that
House panel slams drug company CEO for EpiPen price hikes
Dallas Morning News / Posted 8 days ago
a backlog of generic drugs under review. Regulators said earlier this year that potential competitor for the EpiPen from Teva Pharmaceuticals had problems with its application and should not be expected to hit the market until 2017 or... Read more
287 related stories
8d
Daily Herald
Chaffetz questions executive pay, EpiPen profitsfor Mylan's EpiPen. The agency has a backlog of generic drugs under review, in
Chaffetz questions executive pay, EpiPen profits
Daily Herald / Posted 8 days ago
for Mylan's EpiPen. The agency has a backlog of generic drugs under review, including a version of EpiPen from competitor Teva Pharmaceuticals. But the company said earlier this year that regulators had found problems with its application. Teva's... Read more
287 related stories
8d
Newsmax
FDA Questioned on Generic Alternatives to EpiPenfor Mylan's EpiPen. The agency has a backlog of generic drugs under review, in
FDA Questioned on Generic Alternatives to EpiPen
Newsmax / Posted 8 days ago
for Mylan's EpiPen. The agency has a backlog of generic drugs under review, including a version of EpiPen from competitor Teva Pharmaceuticals. But the company said earlier this year that regulators had found problems with its application. Teva's... Read more
17 related stories
8d
News Channel 12 New Bern
Chaffetz questions executive pay, EpiPen profitsfor Mylan's EpiPen. The agency has a backlog of generic drugs under review, in
Chaffetz questions executive pay, EpiPen profits
News Channel 12 New Bern / Posted 8 days ago
for Mylan's EpiPen. The agency has a backlog of generic drugs under review, including a version of EpiPen from competitor Teva Pharmaceuticals. But the company said earlier this year that regulators had found problems with its application. Teva's... Read more
287 related stories
8d
WBNG Binghamton
FDA official discusses generic version of EpiPenfor Mylan's EpiPen. The agency has a backlog of generic drugs under review, in
FDA official discusses generic version of EpiPen
WBNG Binghamton / Posted 8 days ago
for Mylan's EpiPen. The agency has a backlog of generic drugs under review, including a version of EpiPen from competitor Teva Pharmaceuticals. But the company said earlier this year that regulators had found problems with its application. Teva's... Read more
17 related stories
8d
Fortune
Mylan's Stock Is the Lowest It's Been in 30 YearsEpiPen for $300, half the price of the branded product, as it tries to quell th
Mylan's Stock Is the Lowest It's Been in 30 Years
Fortune / Posted 8 days ago
EpiPen for $300, half the price of the branded product, as it tries to quell the backlash. Further competition looms from Teva Pharmaceutical Industries teva, which hopes to start selling an EpiPen-like device by 2018. Chen also said investors... Read more
4 related stories
8d
NBC News
Mylan CEO defends epic EpiPen price hike in senate hearingit approves competitors — including why it took two years to reject the applica
Mylan CEO defends epic EpiPen price hike in senate hearing
NBC News / Posted 8 days ago
it approves competitors — including why it took two years to reject the application for an epinephrine delivery device from Teva, a pharmaceutical company whose $40 billion takeover bid Mylan rebuffed in 2015. In response to the backlash, Mylan... Read more
17 related stories
9d
Business Wire
UGG Shows at London Fashion Weekfor both everyday casual lifestyle use and high performance activities. The Com
UGG Shows at London Fashion Week
Business Wire / Posted 9 days ago
for both everyday casual lifestyle use and high performance activities. The Company’s portfolio of brands includes UGG®, Teva®, Sanuk®, Ahnu®, HOKA ONE ONE® and Koolaburra®. Deckers Brands products are sold in more than 50 countries and... Read more
9d
Reuters
West Virginia investigating Mylan over EpiPen pricingand bee stings. Morrissey said in Tuesday's petition that Mylan may have viola
West Virginia investigating Mylan over EpiPen pricing
Reuters / Posted 9 days ago
and bee stings. Morrissey said in Tuesday's petition that Mylan may have violated the state's Antitrust Act by suing Teva Pharmaceutical Industries Ltd for patent infringement to prevent it from launching a generic competitor to the... Read more
8 related stories
9d
Channel NewsAsia
West Virginia investigating Mylan over EpiPen pricingand bee stings. Morrissey said in Tuesday's petition that Mylan may have viola
West Virginia investigating Mylan over EpiPen pricing
Channel NewsAsia / Posted 9 days ago
and bee stings. Morrissey said in Tuesday's petition that Mylan may have violated the state's Antitrust Act by suing Teva Pharmaceutical Industries Ltd for patent infringement to prevent it from launching a generic competitor to the... Read more
8 related stories
9d
Reuters
Mylan shares languish at low valuation as EpiPen hearing nearsEpiPen for $300, half the price of the branded product, as it tries to quell th
Mylan shares languish at low valuation as EpiPen hearing nears
Reuters / Posted 9 days ago
EpiPen for $300, half the price of the branded product, as it tries to quell the backlash. Further competition looms from Teva Pharmaceutical Industries, which hopes to start selling an EpiPen-like device by 2018. Chen also said investors were... Read more
4 related stories
9d
FOX Business
Mylan Shares Languish At Low Valuation As Epipen Hearing NearsEpiPen for $300, half the price of the branded product, as it tries to quell th
Mylan Shares Languish At Low Valuation As Epipen Hearing Nears
FOX Business / Posted 9 days ago
EpiPen for $300, half the price of the branded product, as it tries to quell the backlash. Further competition looms from Teva Pharmaceutical Industries, which hopes to start selling an EpiPen-like device by 2018. Chen also said investors were... Read more
4 related stories
9d
FOX Business
Mylan Shares Languish At Low Valuation As Epipen Hearing NearsEpiPen for $300, half the price of the branded product, as it tries to quell th
Mylan Shares Languish At Low Valuation As Epipen Hearing Nears
FOX Business / Posted 9 days ago
EpiPen for $300, half the price of the branded product, as it tries to quell the backlash. Further competition looms from Teva Pharmaceutical Industries, which hopes to start selling an EpiPen-like device by 2018. Chen also said investors were... Read more
4 related stories
9d
Channel NewsAsia
Mylan shares languish at low valuation as EpiPen hearing nearsEpiPen for US$300, half the price of the branded product, as it tries to quell
Mylan shares languish at low valuation as EpiPen hearing nears
Channel NewsAsia / Posted 9 days ago
EpiPen for US$300, half the price of the branded product, as it tries to quell the backlash. Further competition looms from Teva Pharmaceutical Industries , which hopes to start selling an EpiPen-like device by 2018. Chen also said investors were... Read more
4 related stories
9d
Raw Story
West Virginia investigating Mylan over EpiPen pricingand bee stings.Morrissey said in Tuesday’s petition that Mylan may have violate
West Virginia investigating Mylan over EpiPen pricing
Raw Story / Posted 9 days ago
and bee stings.Morrissey said in Tuesday’s petition that Mylan may have violated the state’s Antitrust Act by suing Teva Pharmaceutical Industries Ltd for patent infringement to prevent it from launching a generic competitor to the... Read more
17 related stories
9d
Reuters
West Virginia investigating Mylan over EpiPen pricingand bee stings. Morrissey said in Tuesday's petition that Mylan may have viola
West Virginia investigating Mylan over EpiPen pricing
Reuters / Posted 9 days ago
and bee stings. Morrissey said in Tuesday's petition that Mylan may have violated the state's Antitrust Act by suing Teva Pharmaceutical Industries Ltd (TEVA.TA) for patent infringement to prevent it from launching a generic competitor to the... Read more
17 related stories
9d
Reuters
Allergan pays top dollar for 'stepping stones' from neurology to dermatologynow has the money to embark on a major acquisition spree thanks to the sale of
Allergan pays top dollar for 'stepping stones' from neurology to dermatology
Reuters / Posted 9 days ago
now has the money to embark on a major acquisition spree thanks to the sale of its generic drug portfolio to Teva Pharmaceutical Industries Ltd (TEVA.TA). Allergan received $33.4 billion in cash and $5.1 billion in Teva stock last... Read more
9d
Channel NewsAsia
Allergan pays top dollar for 'stepping stones' from neurology to dermatologynow has the money to embark on a major acquisition spree thanks to the sale of
Allergan pays top dollar for 'stepping stones' from neurology to dermatology
Channel NewsAsia / Posted 9 days ago
now has the money to embark on a major acquisition spree thanks to the sale of its generic drug portfolio to Teva Pharmaceutical Industries Ltd . Allergan received US$33.4 billion in cash and US$5.1 billion in Teva stock last month as... Read more
9d
Detroit Free Press
The Market In 5 Minutes: Traders await FOMC meetingtransaction commonly associated with that same crisis, of course." SRPT GM SBU
The Market In 5 Minutes: Traders await FOMC meeting
Detroit Free Press / Posted 9 days ago
transaction commonly associated with that same crisis, of course." SRPT GM SBUX MSFT ASNA LEN REGN F JPM GOOGL PTCT NVDA TEVA KBH CSCO #TerenceCrutcher The Police Department in Tulsa, Oklahoma, released video of an encounter during which, the... Read more
9d
Newsmax
New IUD Birth Control Device Approvedand Prevention. Hormonal IUDs such as Kyleena are marginally more effective th
New IUD Birth Control Device Approved
Newsmax / Posted 9 days ago
and Prevention. Hormonal IUDs such as Kyleena are marginally more effective than commonly used copper IUDs, such as Teva Pharmaceutical Industries Ltd's Paragard, which last longer but do not help control blood flow. After using Kyleena for... Read more
10d
The New Zealand Herald
US sandal company creates an Ugg-hybrid sandal shoesuch an iconic shoe, you wouldn't think anyone would mess with it. Well, brace
US sandal company creates an Ugg-hybrid sandal shoe
The New Zealand Herald / Posted 10 days ago
such an iconic shoe, you wouldn't think anyone would mess with it. Well, brace yourselves. Popular American sandal brand Teva have teamed up with Ugg to create "something that is familiar, yet remarkably different," the Teva x Ugg Hybrid. Yep,... Read more
10d
The Palm Beach Post
Ugg, Teva join forces, create 'ugliest shoe ever made'brands have joined forces to create a new line of footwear, and they want you t
Ugg, Teva join forces, create 'ugliest shoe ever made'
The Palm Beach Post / Posted 10 days ago
brands have joined forces to create a new line of footwear, and they want you to "suspend your disbelief." Ugg and Teva, both divisions of Deckers Brands, teamed up to produce unique boot and sandal designs reminiscent of both brands'... Read more
6 related stories
10d
Dayton Daily News
Ugg, Teva join forces, create 'ugliest shoe ever made'brands have joined forces to create a new line of footwear, and they want you t
Ugg, Teva join forces, create 'ugliest shoe ever made'
Dayton Daily News / Posted 10 days ago
brands have joined forces to create a new line of footwear, and they want you to "suspend your disbelief." Ugg and Teva, both divisions of Deckers Brands, teamed up to produce unique boot and sandal designs reminiscent of both brands'... Read more
6 related stories
More

People in this news